The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcome of cetuximab plus irinotecan in relation to RAS and BRAF mutational status in patients with colorectal cancer prior treated with a fluoropyrimidine, oxaliplatin and irinotecan.
 
Jesper Andreas Palshof
Research Funding - Merck KGaA (Inst)
 
Troels Dreier Christensen
No Relationships to Disclose
 
Tim Svendstrup Poulsen
No Relationships to Disclose
 
Benny Vittrup Jensen
No Relationships to Disclose
 
Dorte Linnemann
No Relationships to Disclose
 
Jakob Vasehus Schou
No Relationships to Disclose
 
Per Pfeiffer
Research Funding - Amgen (Inst); Merck Serono (Inst); Roche (Inst); Taiho Pharmaceutical (Inst)
 
Mette K. N. Yilmaz
No Relationships to Disclose
 
Ib Jarle Christensen
No Relationships to Disclose
 
Estrid V. Høgdall
No Relationships to Disclose
 
Dorte Nielsen
No Relationships to Disclose